Shopify : NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS OF SHOPIFY INC - Form 6-K
NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS OF SHOPIFY INC. To the shareholders of Shopify Inc.: ...
Source: marketscreener.com
📰 Registration Statements News
Page 2 - Registration Statements News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Registration Statements. Real-time updates on events, politics, business and more.
Perion Network : FORM S-8-REGISTRATION STATEMENT
As filed with the United States Securities and Exchange Commission on May 2 ,2024 Registration No. 333- _____________ ...
Source: marketscreener.com
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--May 1, 2024--
Source: eagletribune.com
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking ...
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study
Comunidad Autonoma De Cataluna United States Israel General Teresa Macarulla Universitario Vall Bristol Myers Squibb
Source: eagletribune.com
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...
Source: marketscreener.com
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024 -April 09, 2024 at 07:09 am EDT
- Data supports CLD-101 and CLD-201’s first-in-class use of stem cells to protect and potentiate antitumor virotherapies designed improve antitumor activity in the clinic. ...
United States San Diego Calidi Biotherapeutics Antoniof Santidrian Allan Camaisa Calidi Biotherapeutics Inc
Source: marketscreener.com
Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients -April 03, 2024 at 07:06 am EDT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of...
Source: marketscreener.com
Shell : NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU AND UK MARKET ABUSE REGIMES - Form 6-K -April 03, 2024 at 01:22 pm EDT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN ISSUER ...
Source: marketscreener.com
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...
Source: marketscreener.com
6K: Reports Fourth Quarter and Full Year 2023 Financial Results -Amendment -March 13, 2024 at 09:02 am EDT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF...
Source: marketscreener.com